Portal de Periódicos da CAPES

Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial

2013; Oxford University Press; Volume: 57; Issue: 3 Linguagem: Inglês

10.1093/cid/cit253

1537-6591

Emanuele Durante‐Mangoni, Giuseppe Signoriello, Roberto Andini, A. Mattei, Maria De Cristoforo, Patrizia Murino, Matteo Bassetti, P Malacarne, Nicola Petrosillo, Nicola Galdieri, Paola Elvira Mocavero, Antonio Corcione, Claudio Viscoli, Raffaele Zarrilli, Ciro Gallo, Riccardo Utili,

Antibiotics Pharmacokinetics and Efficacy

Background. Extensively drug-resistant (XDR) Acinetobacter baumannii may cause serious infections in critically ill patients. Colistin often remains the only therapeutic option. Addition of rifampicin to colistin may be synergistic in vitro. In this study, we assessed whether the combination of colistin and rifampicin reduced the mortality of XDR A. baumannii infections compared to colistin alone.